ArticleCancer chemotherapy and pharmacology2026
Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PPARγ suppresses the tumorigenesis of retroperitoneal liposarcoma via inactivation of the PI3K/AKT signaling pathway.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTAS-115 is an oral multi-kinase inhibitor currently under development for the treatment of osteosarcoma and chronic fibrosing interstitial lung diseases with a progressive phenotype. In this study, we evaluated the effect of multiple administrations of TAS-115 on the pharmacokinetic (PK) changes in CYP2C8, CYP2C9, and CYP3A4 substrates, as well as its anti-tumor efficacy and safety in patients with solid tumors.
methodsPatients received a single oral dose of pioglitazone (CYP2C8 substrate) followed by a cocktail dose of losartan (CYP2C9 substrate) and midazolam (CYP3A4 substrate), both before and during the period of multiple oral TAS-115 doses to evaluate the impact on individual drug PKs with and without TAS-115. Patients who met the inclusion criteria received multiple administrations of TAS-115 in a 21-day cycle (5 days on, 2 days off) until the treatment discontinuation criteria were met.
resultsTAS-115 increased the area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for pioglitazone, losartan, midazolam and 1-hydroxymidazolam by a geometric mean ratio (GMR) of 1% (90% confidence interval: 0.91–1.12), 11% (0.97–1.26), -7% (0.84–1.03) and 5% (0.95–1.15), respectively. No additional or unexpected toxicities occurred. The overall response rate (ORR) was 6.3% and the disease control rate (DCR) was 37.5% for patients with solid tumors, including ORR of 25% and DCR of 50% for four patients with osteosarcoma.
conclusionTAS-115 had a limited impact on drug-drug interactions mediated by CYP2C8, CYP2C9, and CYP3A4. Further, the antitumor efficacy and safety profile of TAS-115 suggest its potential as a treatment option for osteosarcoma. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: jRCT2031210372, October 11, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.